鐳223用於轉移性賀爾蒙抗性攝護腺癌之治療劑量與臨床結果比較

單一醫學中心治療經驗

蔡勝閔1、劉建良2,蘇家震1、李高漢1、謝昆霖1、黃冠華1

台南永康奇美醫學中心 外科部 泌尿科1,泌尿腫瘤科2

Comparison of Dosage and Clinical Outcome of Ra-223 in mCRPC: Real World Data from Single Center

Sheng-Min Tsai1Chien-Liang Liu1Chia-Cheng Su1Kau-Han Li1Kun-Lin Hsieh1Steven K. Huang1

1Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan;

2Division of Uro-Oncology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan;

 

Purpose:

Chemotherapy, novel hormonal agents and radium-223 have shown robust evidence of survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Besides, radium-223 has better health related quality of life (HRQoL) benefit in symptomatic patients. However, expensive medical cost of radium-223 is a major concern for patients. Radium-223 has been approved in Taiwan's National Health Insurance System since 2019 and the therapy of Radium-223 became affordable. Our aim is to review the patients underwent Radium-223 in our institution since 2019.

Material and Methods:

We retrospectively reviewed patients with prostate cancer and received treatment of Ra-223 at the Chi Mei Medical Center between 2019/1 and 2022/9. We excluded patients with mHSPC and visceral metastasis. In total, 28 patients were enrolled and categorized by dosage of Ra-223. The outcomes of interest included overall survival (OS), survival interval since Ra- 223 use and time to opioid use

Results:

The patients were divided into high dosage group (5 or 6 dosage) and incomplete treatment group (less then 4 dosage). The high dosage group has better OS (median 34.5 vs 12.5months) and superior survival interval since Ra-223 use (median 13 vs 4months). On comparison of time to opioid use, patients with 6 dosages have more benefit then 5 dosage and incomplete treatment group (median 13 vs 6 vs 3.5months).

Conclusion:

Benefit of survival outcome, time to opioid use and survival interval since Ra-223 use is strongly related with the dosage. The trend is compatible with the ALSYMPCA trial in 2013.
    位置
    資料夾名稱
    摘要
    發表人
    TUA會計採購組
    單位
    台灣泌尿科醫學會
    標籤
    討論式海報
    建立
    2023-01-02 23:38:16
    最近修訂
    2023-01-02 23:38:51
    1. 1.
      Podium 01
    2. 2.
      Podium 02
    3. 3.
      Podium 03
    4. 4.
      Podium 04
    5. 5.
      Moderated Poster 01
    6. 6.
      Moderated Poster 02
    7. 7.
      Non-Discussion Poster